Understand the source comparison
SS-LUP-332 Review 2026: Comparison Table
The table below compares SS-LUP-332 to other research compounds frequently discussed in metabolic and performance research contexts. Each column reflects the primary mechanism, observed effects in available models, and the current state of human evidence as of
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares SS-LUP-332 to other research compounds frequently discussed in metabolic and performance research contexts. Each column reflects the primary mechanism, observed effects in available models, and the current state of human evidence as of 2026.
- SS-LUP-332
- ERβ agonist / PPAR delta activation
- Mitochondrial biogenesis, increased fat oxidation at rest and during activity
- 35% increase in time to exhaustion (rodent model)
- None—preclinical only
- Mechanistically distinct but zero human safety or efficacy data; translational uncertainty high
- Semaglutide
- GLP-1 receptor agonist
- Appetite suppression via hypothalamic signaling, delayed gastric emptying
- No direct effect—weight loss improves endurance indirectly
- Extensive Phase 3 data; FDA-approved for obesity
- Gold standard for pharmacological weight loss; mechanism unrelated to SS-LUP-332
- Cardarine (GW501516)
- PPAR delta agonist
- Increased fat oxidation, shifts RER toward lipid utilization
- 68% increase in run time (rodent model, 3 weeks)
- No completed human trials; development halted due to cancer risk in rodents
- Shares PPAR delta pathway with SS-LUP-332 but carries documented oncogenic risk
- Tesofensine
- Norepinephrine/dopamine/serotonin reuptake inhibitor
- CNS-driven appetite suppression and thermogenesis
- No direct effect
- Phase 2 data show 10–12% weight loss at 24 weeks; not FDA-approved
- Effective but mechanism is CNS stimulation, not mitochondrial adaptation
- AOD9604
- Modified C-terminal fragment of growth hormone
- Claimed lipolytic effect without IGF-1 elevation
- None documented
- No peer-reviewed human trials demonstrating efficacy
- Marketed heavily but mechanistic plausibility weak; no credible evidence
- SS-LUP-332 occupies a unique position mechanistically—it targets the same PPAR delta pathway as Cardarine (GW501516) but does so through ERβ activation rather than direct PPAR delta agonism. Cardarine was discontinued in human development after rodent studies demonstrated dose-dependent tumor growth in multiple organs, raising the question of whether chronic PPAR delta activation—regardless of upstream pathway—carries similar oncogenic risk. No long-term toxicology data exist for SS-LUP-332, so this remains an open question.